Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced plans to relocate and expand their headquarters in Naperville, Illinois to support the full U.S. commercial launch of its Cordella™ Heart Failure System and Pulmonary Artery (PA) Sensor, pending pre-market approval (PMA) of the sensor by the U.S. Food & Drug Administration (FDA). The new building will significantly increase Endotronix’s manufacturing and operating capacity, allowing for a 30% workforce expansion as well as continued growth opportunities in the years to come. In addition to the U.S. office, Endotronix will maintain their European office in Ireland.
Continue Reading on PR Newswire
